Miebo (perfluorohexyloctane/PF)

It isessential that the manufacturer's labeling be consulted for more detailed information on dosage and administration of this drug. Dosage summary:

Apply topically to the eye as an ophthalmic solution.

Instill one drop of perfluorohexyloctane four times daily into each eye.

To administer the drug, remove the cap from the eye drop bottle. Hold the bottle upright and gently squeeze the bottle. While squeezing, turn the bottle upside down and release the pressure (drawing air into the bottle). Keep the bottle upside down, place the bottle above the eye and squeeze it again to release a drop into the eye. Repeat these steps for the second affected eye.

No dosing information is available for this tab.

No dosing information is available for this tab.

There is no enhanced messaging for this drug.

There are no contraindication interactions for this drug.

There are no severe interactions for this drug.

There are no moderate interactions for this drug.

*Patients with a history of hypersensitivity reaction to perfluorohexyloctane.

There are no contraindication contraindications for this drug.

There are no severe contraindications for this drug.

There are no moderate contraindications for this drug.

Most common ocular adverse reaction was blurred vision. Blurred vision was reported in less than 4% of individuals.

There are no severe adverse reactions for this drug.

There are no less severe adverse reactions for this drug.

No enhanced messaging available.

The safety and effectiveness of perfluorohexyloctane in pediatric patients <18 years have not been established.

There are no adequate and well controlled studies with perfluorohexyloctane in pregnant women.

In animal reproduction studies with oral administration of perfluorohexyloctane during the period of organogenesis, no adverse maternal or developmental effects were observed in rats at doses up to 162 times the recommended human ophthalmic dose (RHOD). Maternal toxicity, miscarriages, and reduced fetal weights were observed in rabbits at all doses tested, with the lowest dose as 41 times the RHOD.

All pregnancies have a risk of birth defect, loss, or other adverse outcomes. In the US general population, the estimated background risk of major birth defects is 2 to 4%, and of miscarriage is 15 to 20%, of clinically recognized pregnancies.

There are no data on the presence of perfluorohexyloctane in human milk, the effects on the breastfed infant, or the effects on milk production. The lack of clinical data during lactation precludes a clear determination of the risk of perfluorohexyloctane to an infant during lactation; however, the developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for perfluorohexyloctane.

No overall differences in safety and effectiveness have been observed between elderly and younger patients.